Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESIFOR: Statin Intolerance N-of-1 Trial
NCT06804980Phase 4Recruiting
- Sponsor
- Minneapolis Heart Institute Foundation
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of rosuvastatin in hypercholesterolemia and cardiovascular disease (CVD) (2 arms), sponsored by Minneapolis Heart Institute Foundation. Primary endpoints: Musculoskeletal symptom presence/absence at 9 months, Statin Tolerance at 9 months and 1 more. Started Feb 2025; status: recruiting.
02
Drugs
rosuvastatin
03
Conditions
hypercholesterolemiacardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT06804980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06804980.